- Home
- CGEN vs PLBY Comparison
CGEN vs PLBY Comparison
Compare CGEN & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- PLBY
- Stock Information
- Founded
- CGEN 1993
- PLBY 1953
- Country
- CGEN Israel
- PLBY United States
- Employees
- CGEN N/A
- PLBY N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- PLBY Recreational Games/Products/Toys
- Sector
- CGEN Health Care
- PLBY Consumer Discretionary
- Exchange
- CGEN Nasdaq
- PLBY Nasdaq
- Market Cap
- CGEN 125.3M
- PLBY 139.8M
- IPO Year
- CGEN 2000
- PLBY N/A
- Fundamental
- Price
- CGEN $1.65
- PLBY $1.66
- Analyst Decision
- CGEN
- PLBY Strong Buy
- Analyst Count
- CGEN 0
- PLBY 1
- Target Price
- CGEN N/A
- PLBY $3.00
- AVG Volume (30 Days)
- CGEN 324.9K
- PLBY 409.7K
- Earning Date
- CGEN 11-10-2025
- PLBY 11-12-2025
- Dividend Yield
- CGEN N/A
- PLBY N/A
- EPS Growth
- CGEN N/A
- PLBY N/A
- EPS
- CGEN N/A
- PLBY N/A
- Revenue
- CGEN $6,903,000.00
- PLBY $136,084,000.00
- Revenue This Year
- CGEN N/A
- PLBY $5.20
- Revenue Next Year
- CGEN $208.08
- PLBY $8.32
- P/E Ratio
- CGEN N/A
- PLBY N/A
- Revenue Growth
- CGEN N/A
- PLBY N/A
- 52 Week Low
- CGEN $1.13
- PLBY $0.90
- 52 Week High
- CGEN $2.66
- PLBY $2.44
- Technical
- Relative Strength Index (RSI)
- CGEN 46.42
- PLBY 71.26
- Support Level
- CGEN $1.54
- PLBY $1.26
- Resistance Level
- CGEN $1.79
- PLBY $1.79
- Average True Range (ATR)
- CGEN 0.11
- PLBY 0.08
- MACD
- CGEN -0.01
- PLBY 0.05
- Stochastic Oscillator
- CGEN 34.62
- PLBY 80.19
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About PLBY PLBY Group Inc.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.